{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:37:18Z","timestamp":1770417438681,"version":"3.49.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The expression of CD20 in precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with poor outcomes. The addition of rituximab to intensive chemotherapy in CD20+ ALL has led to improved outcomes in several studies. However, there is no clear evidence regarding the optimal number of doses and its benefit without an allogeneic stem cell transplant. Achieving measurable residual disease (MRD)-negative status postinduction would reduce the requirement for a transplant. Novel approaches are needed to induce a higher proportion of MRD-negative complete remission in patients with high-risk ALL. Given bortezomib\u2019s activity in relapsed ALL and its synergism with rituximab in B-cell lymphomas, the addition of bortezomib to rituximab and chemotherapy may provide an incremental benefit in CD20+ precursor B-ALL. We conducted a phase 2 study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults (aged &amp;gt;14 years) with CD20+, Philadelphia-negative precursor B-ALL; bone marrow MRD negativity at the end of induction was the primary end point. From December 2017 through August 2019, a total of 35 patients were enrolled. End-of-induction MRD-negative status was achieved in 70.9% of patients, as opposed to 51.7% in the historical cohort treated with chemotherapy alone. MRD-negative rates improved to 87.5% post-consolidation. At a median follow-up of 21 months, event-free survival and overall survival rates were 78.8% (95% confidence interval, 66-94) and 78.7% (95% confidence interval, 65.8-94), respectively. There was no significant increase in toxicity with bortezomib and rituximab compared with the historical cohort. The incidence of neuropathy was 26% (all less than grade 3). The combination of bortezomib, rituximab, and a pediatric-inspired ALL regimen was active and well tolerated in de novo CD20+ Philadelphia-negative precursor B-ALL. This trial was registered with the Clinical Trials Registry-India as CTRI\/2017\/04\/008393(http:\/\/ctri.nic.in\/Clinicaltrials).<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003368","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:57:53Z","timestamp":1630364273000},"page":"3436-3444","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Bortezomib and rituximab in de novo adolescent\/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7065","authenticated-orcid":false,"given":"Hasmukh","family":"Jain","sequence":"first","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-5682","authenticated-orcid":false,"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-2503","authenticated-orcid":false,"given":"Vasu Babu","family":"Goli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashree","family":"Thorat","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-0415","authenticated-orcid":false,"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory, ACTREC,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanlaxmi","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Cytogenetics, ACTREC,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. N. Avinash","family":"Bonda","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-795X","authenticated-orcid":false,"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-5937","authenticated-orcid":false,"given":"P. G.","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory, ACTREC,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-2857","authenticated-orcid":false,"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory, ACTREC,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-0509","authenticated-orcid":false,"given":"Neha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Adult Hematolymphoid Unit, Department of Medical Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Clinical Research Secretariat, Mumbai, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Gujral","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"1","key":"2021090915301293200_B1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802 [published correction appears in Cancer. 2014;120(14):2222]","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer."},{"issue":"12","key":"2021090915301293200_B2","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"MRC\/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood."},{"issue":"24","key":"2021090915301293200_B3","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021090915301293200_B4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol."},{"issue":"5","key":"2021090915301293200_B5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021090915301293200_B6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study [published correction appears in J Clin Oncol. 2009;27(15):2574]","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021090915301293200_B7","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in adult ALL?","volume":"120","author":"Br\u00fcggemann","year":"2012","journal-title":"Blood."},{"key":"2021090915301293200_B8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/leusup.2012.4","article-title":"Change in prognostic factors","volume":"1","author":"Hoelzer","year":"2012","journal-title":"Leuk Suppl."},{"issue":"25","key":"2021090915301293200_B9","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood."},{"issue":"10","key":"2021090915301293200_B10","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood."},{"issue":"21","key":"2021090915301293200_B11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL Study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood."},{"issue":"23","key":"2021090915301293200_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.1.1","article-title":"Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized GRALL-R 2005 study","volume":"126","author":"Maury","year":"2015","journal-title":"Blood."},{"key":"2021090915301293200_B13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2019-123374","article-title":"First analysis of the UKALL14 phase 3 randomised trial to determine if the addition of rituximab to standard induction chemotherapy improves EFS in adults with precursor B-ALL (CRUK\/09\/006)","volume":"134","author":"Marks","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2021090915301293200_B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"2021090915301293200_B15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/14737140.5.3.465","article-title":"Proteasome inhibition as a therapeutic strategy for hematologic malignancies","volume":"5","author":"Mitsiades","year":"2005","journal-title":"Expert Rev Anticancer Ther."},{"issue":"1","key":"2021090915301293200_B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia."},{"issue":"2","key":"2021090915301293200_B17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2021090915301293200_B18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.14505","article-title":"The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood","volume":"176","author":"Bertaina","year":"2017","journal-title":"Br J Haematol."},{"issue":"2","key":"2021090915301293200_B19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol."},{"issue":"8","key":"2021090915301293200_B20","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood."},{"issue":"5","key":"2021090915301293200_B21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2020003526","article-title":"Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol","volume":"5","author":"Rajendra","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"2021090915301293200_B22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/GO.20.00240","article-title":"Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an Indian tertiary care center","volume":"6","author":"Jain","year":"2020","journal-title":"JCO Glob Oncol."},{"issue":"22","key":"2021090915301293200_B23","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood.V128.22.4005.4005","article-title":"Therapeutic drug monitoring of posaconazole in adult acute myeloid leukemia (AML) patients receiving posaconazole prophylaxis during induction: experience from a center with high invasive fungal infection (IFI) burden","volume":"128","author":"Sengar","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2021090915301293200_B24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cyto.b.21831","article-title":"A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: a study of 622 patients","volume":"98","author":"Tembhare","year":"2020","journal-title":"Cytometry B Clin Cytom."},{"issue":"14","key":"2021090915301293200_B25","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood."},{"key":"2021090915301293200_B26","doi-asserted-by":"crossref","first-page":"e21008","DOI":"10.1200\/jco.2015.33.15_suppl.e21008","article-title":"Clinical significance of minimal residual disease in peripheral blood on day 8 induction in childhood B-precursor acute lymphoblastic leukemia: Report from Children\u2019s Cancer Hospital in Egypt","volume":"33","author":"Gohar","year":"2015","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021090915301293200_B27","doi-asserted-by":"crossref","first-page":"31179","DOI":"10.1038\/srep31179","article-title":"Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemia","volume":"6","author":"Salina","year":"2016","journal-title":"Sci Rep."},{"issue":"21","key":"2021090915301293200_B28","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V118.21.2583.2583","article-title":"Prevalence and patterns of cytomegalovirus (CMV) reactivation in adult acute lymphoblastic leukemia patients on chemotherapy: single center experience","volume":"118","author":"Gulia","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2021090915301293200_B29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ejh.13366","article-title":"Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis","volume":"104","author":"Sharpley","year":"2020","journal-title":"Eur J Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3436\/1821413\/advancesadv2020003368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3436\/1821413\/advancesadv2020003368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T01:09:46Z","timestamp":1699405786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/17\/3436\/476715\/Bortezomib-and-rituximab-in-de-novo-adolescent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003368","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]}}}